Phase II Study of Afatinib as Third‐Line Treatment for Patients in Korea With Stage IIIB/IV Non‐Small Cell Lung Cancer Harboring Wild‐Type
EGFR
Keyword(s):
Phase Ii
◽
Keyword(s):
2009 ◽
Vol 15
(3)
◽
pp. 555-559
Keyword(s):
2009 ◽
Vol 71
(2)
◽
pp. 117-126
◽
Keyword(s):